Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Recruiting now · Phase 1

Conditions studied: Solid Tumor

In brief

This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with bulky tumors who have failed standard therapy. At least 9 participants will be enrolled in this study.

Key facts

Study ID: NCT06349837
Run by: Sichuan University
People needed: 24
Starts: 2024-04-18
Expected to finish: 2028-11-30
Last updated by the study team: 2026-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Be willing and able to provide written informed consent/assent for the trial.
Be ≥18 years of age on day of signing informed consent.
Patients with histologically or cytologically confirmed stage IV solid tumours.
Be willing to undergo repeat biopsy of tumor lesions according to the study protocol.
Patients who have failed the standard therapy, or who are unsuitable for standard treatment, or refuse chemotherapy.
At least one measurable lesion according to RECIST 1.1. A lesion that has previously received radiotherapy can be considered a target lesion only if this lesion is clearly progressed after radiotherapy.
The target lesions (irradiated lesions) are > 5cm in in diameter
ECOG 0-2.
Life expectancy of > 3 months.
Subjects should agree to use an adequate method of contraception.

You may not qualify if…

Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis and/or spinal cord compression, etc.
With oncologic emergencies that require immediate treatment
EGFR/ALK/ROS-1 mutation or mutation status unknown.
Has evidence of interstitial lung disease or active and/or non-infectious pneumonitis (drug-induced pneumonia, radiation-induced pneumonia, etc.) requiring steroid therapy.
History of pulmonary fibrosis, pulmonary hypertension, severe irreversible airway obstruction disease
Patients with peripheral neuropathy.
Significant heart disease or impairment of cardiac function
Fluid accumulating in the third space, such as pericardial effusion, pleural effusion and peritoneal effusion that remains uncontrolled by aspiration or other treatment
Known allergy to drugs or excipients, known severe allergic reaction to any of the PD-1 monoclonal antibodies
Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.

Where it is running

West China Hospital, Sichuan University — Chengdu, Sichuan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.